A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Learning lessons from across Europe – the hidden costs of COVID-19 on lung canceron January 27, 2021 at 12:39 am
This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum. Author: Elissa Prichep, Project Lead Precision Medicine, World ...
- Researchers develop virus-based treatment platform to fight pancreatic canceron January 27, 2021 at 12:27 am
Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer. By using the ...
- The Prostate Cancer Foundation And Kristen Bell Honor Caregivers With Fourth Annual True Love Conteston January 27, 2021 at 12:18 am
Beginning February 1st, the Prostate Cancer Foundation (PCF) will launch its Fourth Annual TRUE Love contest to honor family and caregivers for their diligent work in caring for their loved ones or ...
- Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwanon January 27, 2021 at 12:13 am
Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland ...
- Men with breast cancer face higher heart health riskson January 27, 2021 at 12:05 am
Heart disease risk factors are common among men with breast cancer, a new, small study finds. Researchers analyzed the medical records of 24 male breast cancer patients, aged 38 to 79. Half had a ...
- Novel platform uses modified virus to combat pancreatic canceron January 26, 2021 at 8:43 pm
Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer.
- Sperm banks give cancer patients options for family planning as they go through treatmenton January 26, 2021 at 8:25 pm
Testicular cancer tends to occur in younger men between the ages of 20 and 40, and while doctors say it’s highly curable the prognosis can be more complicated for some patients. Kevin Hull ...
- Global Cancer Treatment Drugs Market 2020 Ecosystem Player Profiles, Value Chain and Industry Strategies to 2025on January 26, 2021 at 5:23 pm
Global Cancer Treatment Drugs Market 2020 by Manufacturers, Type and Application, Forecast to 2025 announced by MarketsandResearch.biz provides an expert and in-depth analysis of key business trends ...
- Minnesota teacher with cancer continues virtual classes, even during chemotherapyon January 26, 2021 at 3:52 pm
Kelly Klein is that teacher everyone remembers — even during a year she'd rather forget. Klein isn't only tackling virtual learning. She's doing it while battling a recurrence of ovarian cancer. She's ...
via Bing News